Atopic dermatitis (AD) is a common skin disease characterized by chronic and relapsing inflammatory dermatitis with immunological disturbances. The incidence of atopic dermatitis is continuously increasing worldwide with a prevalence rate of approximately 10–20% and is more common among infants and children.
Most patients with atopic dermatitis have increased circulating eosinophils and immunoglobulin (Ig) E due to elevated interleukin (IL)-4, IL-5, and IL-13 produced by T-helper (Th) 2 cells. Th2 immune responses are known to play an important role in the pathogenic mechanism of atopic dermatitis. In addition, Th1 immune response related to interferon-gamma (IFN-γ) is also associated with the pathophysiology of atopic dermatitis.
Therefore, atopic dermatitis is known to be a biphasic inflammatory skin disease, provoked by Th1/Th2 immune responses. Acute AD skin lesions exhibit Th2 type inflammatory cytokine profiles, whereas the chronic phase is characterized by Th1 type immune responses releasing Th1 cytokines such as IFN-γ and IL-12 and delayed-type hypersensitivity reactions. The imbalance of Th1 and Th2 immune responses plays important roles in the development of atopic dermatitis.
Hydrocortisone cream provides anti-inflammatory, anti-pruritic, and vasoconstrictive actions and topical hydrocortisone therapy is currently the foundation for the management of AD. However, topical hydrocortisone are not used for long periods, because of adverse side effects like burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, and striae.
Accordingly, therapeutics for atopic dermatitis that possess efficacy with a minimal side effect profile are desirable.
Maállo Skin Ointment supports the structure & function of the skin layers and has been formulated to decrease dermatitis stimulus (noted above) and skin damage. As a post therapeutic (after the skin condition has cleared) Maállo supports skin health (without adverse side effects) to sustain remission. To learn more about Maállo click here.
Kátha-Soma supportive care therapeutics help people living with serious illness or slow cell renewal due to aging, minimize their signs & symptoms, achieve daily comfort and maintain quality of life.
DISCLAIMER: The information provided is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition. USA 2015-16